The annual ESC congress recorded four new or updated guidelines. We report some key points related to the management of non-ST segment elevation acute coronary syndromes.
The current hype around SGLT2 inhibitors in the treatment of heart failure patients is more than justified, according to Prof. Martin Cowie
An educational program for patients with atrial fibrillation and their healthcare providers did not result in more oral anticoagulants being administered after one year than with the usual treatment
Patients under successful PCI for angina pectoris and acute coronary syndrome without ST elevation have good long-term results with optimal medical therapy. In the ATPCI study, the routine use of trimetazidine did not lead to a reduction in cardiac events in this patient group.
Restrictive blood transfusion has no negative impact on clinical outcomes compared to more liberal strategies in anemic patients with acute MI. Restrictive strategies resulted in fewer infections and acute lung injuries.
An evaluation of COVID-19 patients admitted to a Wuhan hospital shows that they were at high risk of thromboembolic events and bleeding, as well as an increased risk of mortality.
Modern antidiabetics, such as SGLT2 inhibitors, have shown positive effects on cardiovascular risks or kidney function for diabetics. However, recent study results show an equal benefit for heart failure patients regardless of their diabetes status.
Prof. Casadei talks about what the cardiology field has learnt from the COVID-19 crisis, what positive aspects have emerged from it, and how to turn the profession back into a vocation.
The early practice of rhythm control reduces cardiovascular outcomes in patients with early atrial fibrillation and comorbid cardiovascular conditions compared to current evidence-based standard care.
Recent studies on heart failure treatment showed that SGLT2 inhibitors reduced the risk of cardiovascular death or even hospitalization in heart failure, with reduced ejection fraction compared to placebo.
The cardiovascular risk in diabetes is determined by some comorbidities. Renal dysfunction and micro- and macrovascular events are common. Should diabetes patients be screened for cardiovascular risks?
Tumour treatment with drugs often leads to a rapid loss of strength in patients and increases their cardiovascular risk and general mortality. Accompanying physical training can mitigate these effects.
A research team developed an innovative antibody for chronic anemia treatment in dialysis patients. It allows for a lower EPO dose and the resulting minimization of cardiovascular risk.
According to a recent study, the movements and breathing during yoga have a positive influence on the symptoms in patients with atrial fibrillation.
Just send a selfie to the cardiologist and receive a heart disease risk assessment. Sounds futuristic? It could actually become routine, according to a recent study.
Dr. Vikramjeet Singh is investigating how the interaction of intestinal bacteria and immune cells influences a brain infarction, with a particular focus on microbial diversity in the intestine, and neutrophils.
Hepatitis-C eradication by 2030, as required by the WHO, is within reach in Spain. Dr. Joaquin Cabezas explains how the country is making prisons HCV-free by near 100% diagnosis and 100% treatment.
NAFLD is a form of fatty liver (steatosis hepatitis) not caused by increased alcohol consumption. The prevalence in Europe is estimated to be between 20 and 30%.
Scientists have developed effective antimicrobial glass and basalt fibers. The fibers are effective against different strains of bacteria and fungi and might be used in filters and textiles in the future.
Chronic liver disease is on the rise. Aside from undetected liver disease, abnormal liver function tests are often not followed up in primary care, or many patients ignore their follow-up appointments.